Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of multi-project deals with two undisclosed prominent pharmaceutical companies. The collaborations will focus on using ActivMAb®, Vaccinex’s antibody discovery and novel viral display platform, for antibody discovery against complex antigens such as GPCRs and ion channels. Financial terms of the deals are undisclosed.
https://finance.yahoo.com/news/vaccinex-announces-signing-two-multi-130000730.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.